<p>文艺复兴科技公司在其最近向美国证券交易委员会提交的 13F 文件中表示，在第四季度将其在 Aerovate Therapeutics, Inc.（纳斯达克：AVTE - 免费报告）股票中的持股比例提高了 149.2%。该公司在本季度额外购买了 26,700 股后，持有 44,600 股该公司的股票。根据其最近的 SEC 文件，文艺复兴科技公司持有 Aerovate Therapeutics 0.15% 的股份，价值 118,000 美元。</p>
<p>获取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
<p>其他机构投资者也增加或减少了在该公司的持股。ADAR1 Capital Management LLC 在第四季度将其在 Aerovate Therapeutics 的持股比例提高了 720.7%。ADAR1 Capital Management LLC 现在拥有 928,016 股该公司的股票，价值 2,459,000 美元，此前在该期间内额外购买了 814,941 股。蒙特利尔银行在第四季度将其在 Aerovate Therapeutics 的持股比例提高了 86.8%。蒙特利尔银行现在拥有 59,097 股该公司的股票，价值 157,000 美元，此前在上个季度额外购买了 27,453 股。拉塞尔投资集团有限公司在第四季度将其在 Aerovate Therapeutics 的持股比例提高了 110.7%。拉塞尔投资集团有限公司现在拥有 15,184 股该公司的股票，价值 40,000 美元，此前在上个季度额外购买了 7,977 股。摩根大通在第四季度将其在 Aerovate Therapeutics 的持股比例提高了 1,021.1%。摩根大通现在拥有 67,165 股该公司的股票，价值 178,000 美元，此前在上个季度额外购买了 61,174 股。最后，Corient Private Wealth LLC 在第四季度购买了 Aerovate Therapeutics 的新股份，价值约 98,000 美元。</p>
<h2>Aerovate Therapeutics 价格表现</h2>
<p>Aerovate Therapeutics 的股票在周四开盘价为 10.09 美元。Aerovate Therapeutics, Inc.的 1 年最低价为 43.75 美元，1 年最高价为 884.98 美元。该公司的市值为 2.9246 亿美元，市盈率为-3.37，贝塔值为 0.95。该公司的 50 日简单移动平均线为 78.40 美元，200 日简单移动平均线为 85.32 美元。</p>
<p>Aerovate Therapeutics（纳斯达克：AVTE - 获取免费报告）最后一次发布财报是在 4 月 25 日，周五。该公司报告本季度每股收益（EPS）为-3.15 美元，超出分析师一致预期的-10.50 美元，差额为 7.35 美元。整体来看，研究分析师预计 Aerovate Therapeutics, Inc.在当前年度的每股收益为-2.64 美元。</p>
<h2>Aerovate Therapeutics 宣布分红</h2>
<p>该公司最近还披露了一项分红，已于 4 月 28 日（周一）支付。4 月 25 日（周五）登记在册的股东获得了 84.00 美元的分红。除息日期为 4 月 29 日（周二）。</p>
<h2>Aerovate Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Aerovate Therapeutics, Inc.是一家临床阶段的生物制药公司，开发能够改善美国罕见心肺疾病患者生活的药物。它专注于推进 AV-101，这是一种用于治疗肺动脉高压的干粉吸入剂，目前处于 2b/3 期临床试验中。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Aerovate Therapeutics</li>
<li>投资股票的不同类型</li>
<li>调查：美国最具启发性的女性商业领袖 [2025]</li>
<li>房地产投资信托是否值得在你的投资组合中占有一席之地？</li>
<li>迪士尼股票因财报上涨——这种魔力能持续吗？</li>
<li>如何投资生物科技股票</li>
<li>油价、价值和增长的相关性对市场的影响</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Aerovate Therapeutics 吗？</h2>
<p>在你考虑 Aerovate Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Aerovate Therapeutics 并不在名单上。</p>
<p>虽然 Aerovate Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

AVTE

<p>文艺复兴科技公司（Renaissance Technologies LLC）在 2023 年第四季度将其在 Aerovate Therapeutics, Inc.（NASDAQ:AVTE）的持股增加了 149.2%，额外购买了 26,700 股，使其总持股达到 44,600 股，价值 118,000 美元。其他机构投资者也显著增加了他们的持仓。Aerovate 的股票开盘价为 10.09 美元，市值为 2.9246 亿美元，市盈率为-3.37。该公司最近报告的每股收益（EPS）为-3.15，超出预期，并宣布将于 4 月 28 日支付 84.00 美元的股息</p>

<p>Renaissance Technologies LLC lifted its stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 149.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 44,600 shares of the company's stock after purchasing an additional 26,700 shares during the quarter. Renaissance Technologies LLC owned 0.15% of Aerovate Therapeutics worth $118,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>文艺复兴科技公司在其最近向美国证券交易委员会提交的 13F 文件中表示，在第四季度将其在 Aerovate Therapeutics, Inc.（纳斯达克：AVTE - 免费报告）股票中的持股比例提高了 149.2%。该公司在本季度额外购买了 26,700 股后，持有 44,600 股该公司的股票。根据其最近的 SEC 文件，文艺复兴科技公司持有 Aerovate Therapeutics 0.15% 的股份，价值 118,000 美元。</p>
</div><p>Get <strong>Aerovate Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
</div><p>Other institutional investors have also added to or reduced their stakes in the company. ADAR1 Capital Management LLC boosted its position in shares of Aerovate Therapeutics by 720.7% in the fourth quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company's stock valued at $2,459,000 after acquiring an additional 814,941 shares during the period. Bank of Montreal Can grew its position in shares of Aerovate Therapeutics by 86.8% during the 4th quarter. Bank of Montreal Can now owns 59,097 shares of the company's stock valued at $157,000 after purchasing an additional 27,453 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Aerovate Therapeutics by 110.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,184 shares of the company's stock valued at $40,000 after acquiring an additional 7,977 shares in the last quarter. JPMorgan Chase &amp; Co. boosted its position in shares of Aerovate Therapeutics by 1,021.1% during the 4th quarter. JPMorgan Chase &amp; Co. now owns 67,165 shares of the company's stock valued at $178,000 after acquiring an additional 61,174 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new position in shares of Aerovate Therapeutics in the fourth quarter worth approximately $98,000.</p>
<div class="lb-trans"><p>其他机构投资者也增加或减少了在该公司的持股。ADAR1 Capital Management LLC 在第四季度将其在 Aerovate Therapeutics 的持股比例提高了 720.7%。ADAR1 Capital Management LLC 现在拥有 928,016 股该公司的股票，价值 2,459,000 美元，此前在该期间内额外购买了 814,941 股。蒙特利尔银行在第四季度将其在 Aerovate Therapeutics 的持股比例提高了 86.8%。蒙特利尔银行现在拥有 59,097 股该公司的股票，价值 157,000 美元，此前在上个季度额外购买了 27,453 股。拉塞尔投资集团有限公司在第四季度将其在 Aerovate Therapeutics 的持股比例提高了 110.7%。拉塞尔投资集团有限公司现在拥有 15,184 股该公司的股票，价值 40,000 美元，此前在上个季度额外购买了 7,977 股。摩根大通在第四季度将其在 Aerovate Therapeutics 的持股比例提高了 1,021.1%。摩根大通现在拥有 67,165 股该公司的股票，价值 178,000 美元，此前在上个季度额外购买了 61,174 股。最后，Corient Private Wealth LLC 在第四季度购买了 Aerovate Therapeutics 的新股份，价值约 98,000 美元。</p>
</div><h2>Aerovate Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 价格表现</h2>
</div><p>Shares of Aerovate Therapeutics stock opened at $10.09 on Thursday. Aerovate Therapeutics, Inc. has a 1 year low of $43.75 and a 1 year high of $884.98. The firm has a market cap of $292.46 million, a PE ratio of -3.37 and a beta of 0.95. The company has a 50 day simple moving average of $78.40 and a two-hundred day simple moving average of $85.32.</p>
<div class="lb-trans"><p>Aerovate Therapeutics 的股票在周四开盘价为 10.09 美元。Aerovate Therapeutics, Inc.的 1 年最低价为 43.75 美元，1 年最高价为 884.98 美元。该公司的市值为 2.9246 亿美元，市盈率为-3.37，贝塔值为 0.95。该公司的 50 日简单移动平均线为 78.40 美元，200 日简单移动平均线为 85.32 美元。</p>
</div><p>Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last released its earnings results on Friday, April 25th. The company reported ($3.15) EPS for the quarter, beating analysts' consensus estimates of ($10.50) by $7.35. As a group, research analysts anticipate that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current year.</p>
<div class="lb-trans"><p>Aerovate Therapeutics（纳斯达克：AVTE - 获取免费报告）最后一次发布财报是在 4 月 25 日，周五。该公司报告本季度每股收益（EPS）为-3.15 美元，超出分析师一致预期的-10.50 美元，差额为 7.35 美元。整体来看，研究分析师预计 Aerovate Therapeutics, Inc.在当前年度的每股收益为-2.64 美元。</p>
</div><h2>Aerovate Therapeutics Announces Dividend</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 宣布分红</h2>
</div><p>The firm also recently disclosed a dividend, which was paid on Monday, April 28th. Stockholders of record on Friday, April 25th were issued a $84.00 dividend. The ex-dividend date was Tuesday, April 29th.</p>
<div class="lb-trans"><p>该公司最近还披露了一项分红，已于 4 月 28 日（周一）支付。4 月 25 日（周五）登记在册的股东获得了 84.00 美元的分红。除息日期为 4 月 29 日（周二）。</p>
</div><h2>Aerovate Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.是一家临床阶段的生物制药公司，开发能够改善美国罕见心肺疾病患者生活的药物。它专注于推进 AV-101，这是一种用于治疗肺动脉高压的干粉吸入剂，目前处于 2b/3 期临床试验中。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Aerovate Therapeutics</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Survey: America’s Most Inspirational Women Business Leaders [2025]</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>Disney Stock Jumps on Earnings—Is the Magic Sustainable?</li>
<li>How to Invest in Biotech Stocks</li>
<li>What Oil, Value, and Growth Correlations Say About the Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Aerovate Therapeutics</li>
<li>投资股票的不同类型</li>
<li>调查：美国最具启发性的女性商业领袖 [2025]</li>
<li>房地产投资信托是否值得在你的投资组合中占有一席之地？</li>
<li>迪士尼股票因财报上涨——这种魔力能持续吗？</li>
<li>如何投资生物科技股票</li>
<li>油价、价值和增长的相关性对市场的影响</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AVTE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aerovate Therapeutics 吗？</h2>
</div><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Aerovate Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Aerovate Therapeutics 并不在名单上。</p>
</div><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aerovate Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

文艺复兴科技有限责任公司购入了 Aerovate Therapeutics, Inc.（纳斯达克股票代码：AVTE）的 26,700 股股票